FDA 2022 Study Warns Against High Risk, High Traffic Fever Screening

*** *** ************* *** *********** ** * ******* cameras - *.*.*. ******** ************ (****) - ** **** **** **** ***** subjects. *** **** ****** "****** ********* for ********* ******** **** ************" ***** "may ** ****** ** ******** ******** and ****** ********** ******* *********."

"Little ********" ** ****** ** **** *********

*******, *** ***** **** **** ** past ********* "***** ** ****** ******** that **** ******** [** ***** ****] has **** * *********** ******," ******* because ** ***-******* *******, "*********** **********", and **** ********* **********:

** ******* ****** *********, ***** ********* has **** **** ** ****-******* ***** and ** *** ********* ** ****-**** sites, **** ** ****** ************** ****, hospitals, *** ******** ****** **********, ***there ** ****** ******** **** **** ******** *** **** * *********** ******. This may be due ** **** ** *** ************** ** *********** *************** *** *********** **********, ** **** ** * **** ** ******, ************ ******* ******** ********** *** ********** *** *********. [emphasis added]

**** *****, "*** *** ************* *** also ** ************ ** **** ** the *** ** **** **** ************ performance **************."

******** *** ******* **** "*********", *** study ********** **** *** **** ** "according ** ************ **** *********." ** the ***** ******, **** "******* ******* to ************* *********" ******** ***** ***** ********* **********.

******** ****** ****** ****** ****** *** Covid-19 ********, *** ***-********* ********* ********** *** deployment **** *******, *** ******* ************** ****** ** **** *******.

* ********* *******,************************ ********* *** ********** ** ***** was * ***** ********* ** ************* standards. ***** ************* **** ** ***********(*** ********* ******* *** ******* ********* *** months).

*** ***** **** **** *** ****-******* thermal ******* **** **** ****** ********** than **** ******* **** **** ****** the ********: *** **** ******, **** a *** × *** ***** ******, and *** ******** ******* ***. **** P-series **** * *** × *** pixel ****** (**** *** ***(*) *******).

** **********, *** ******* ****** *** terminal, ***** *** ******* ******* *** "found ** **** **** **% ** NFL ********", *** * *** * 90 ******, ** >* ***** ***** pixels **** *** **** ******. ** some ******* ******, *************** ** ** ***** ** * x * ******.

**** ******* ******** **** **** **** compensating ********** **** **** ************ **** clinical ***. ** ***** ****, **** published* ****-******** ******** ************ **** ********** *********** ************.

Testing **********

*** ***** ****** ****** ***********, **** IRTs **** ********* *** ******** ** non-contact ******** ************ (*****) **** ** the ***** *** **********:

**** ******** *** ****** *********** ** IRTs **** ***** ******** **** **** designed *** ******* ***********,the ******** ******** ** **** **** ****** ** ******* **** **** ** *****. The two IRTs have similar accuracy, and both have better bias and precision than the six models of NCITs, even with the worst regression method.

** *** ******, "**** ***** ** a ****** ****** *** ***** ********* in ****-******* ***** ** ******-**** ********* where *** ****** **** ***** ** justified ** ******* *************."

More ******** ********

**** **** "*********" *******, *** ***** acknowledged **** **** **** **** ***** to ** **** ***** ******* ******* are *********** *** ******** ************. “*********, there *** ** ********* ******* ** evaluate *** ******** ******** ** ****.”